Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Stephen L Chan

Showing results (111-120 of 164) with videos related to

Pageof 17
Sort By:
ESMO Open|August 28, 2020
Second-line cabozantinib after sorafenib treatment for advanced hepatocellular carcinoma: a subgroup analysis of the phase 3 CELESTIAL trialRobin Kate Kelley, Baek-Yeol Ryoo, Philippe Merle, et al.
European Journal of Cancer (Oxford, England : 1990)|April 1, 2022
Updated efficacy and safety of KEYNOTE-224: a phase II study of pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenibMasatoshi Kudo, Richard S Finn, Julien Edeline, et al.
Lancet (London, England)|April 19, 2023
Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a randomised, double-blind, placebo-controlled, phase 3 trialRobin Kate Kelley, Makoto Ueno, Changhoon Yoo, et al.
Cancer|November 24, 2020
Health-related quality-of-life impact of pembrolizumab versus best supportive care in previously systemically treated patients with advanced hepatocellular carcinoma: KEYNOTE-240Baek-Yeol Ryoo, Philippe Merle, Amit S Kulkarni, et al.
The Lancet. Oncology|June 8, 2018
Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trialAndrew X Zhu, Richard S Finn, Julien Edeline, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 3, 2019
Pembrolizumab As Second-Line Therapy in Patients With Advanced Hepatocellular Carcinoma in KEYNOTE-240: A Randomized, Double-Blind, Phase III TrialRichard S Finn, Baek-Yeol Ryoo, Philippe Merle, et al.
Elife|March 23, 2021
Applications of genetic-epigenetic tissue mapping for plasma DNA in prenatal testing, transplantation and oncologyWanxia Gai, Ze Zhou, Sean Agbor-Enoh, et al.
HPB : the Official Journal of the International Hepato Pancreato Biliary Association|February 12, 2020
Prospective double-blinded randomized controlled trial of Microwave versus RadioFrequency Ablation for hepatocellular carcinoma (McRFA trial)Charing C N Chong, Kit F Lee, Sunny Y S Cheung, et al.
The Lancet. Oncology|July 7, 2022
Cabozantinib plus atezolizumab versus sorafenib for advanced hepatocellular carcinoma (COSMIC-312): a multicentre, open-label, randomised, phase 3 trialRobin Kate Kelley, Lorenza Rimassa, Ann-Lii Cheng, et al.
Annals of Internal Medicine|September 16, 2024
Viral Load-Based Prediction of Hepatocellular Carcinoma Risk in Noncirrhotic Patients With Chronic Hepatitis B : A Multinational Study for the Development and External Validation of a New Prognostic ModelGi-Ae Kim, Young-Suk Lim, Seungbong Han, et al.
Pageof 17

Showing results (111-120 of 164) with videos related to

Sort By:
Pageof 17
ESMO Open|August 28, 2020
Second-line cabozantinib after sorafenib treatment for advanced hepatocellular carcinoma: a subgroup analysis of the phase 3 CELESTIAL trialRobin Kate Kelley, Baek-Yeol Ryoo, Philippe Merle, et al.
European Journal of Cancer (Oxford, England : 1990)|April 1, 2022
Updated efficacy and safety of KEYNOTE-224: a phase II study of pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenibMasatoshi Kudo, Richard S Finn, Julien Edeline, et al.
Lancet (London, England)|April 19, 2023
Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a randomised, double-blind, placebo-controlled, phase 3 trialRobin Kate Kelley, Makoto Ueno, Changhoon Yoo, et al.
Cancer|November 24, 2020
Health-related quality-of-life impact of pembrolizumab versus best supportive care in previously systemically treated patients with advanced hepatocellular carcinoma: KEYNOTE-240Baek-Yeol Ryoo, Philippe Merle, Amit S Kulkarni, et al.
The Lancet. Oncology|June 8, 2018
Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trialAndrew X Zhu, Richard S Finn, Julien Edeline, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 3, 2019
Pembrolizumab As Second-Line Therapy in Patients With Advanced Hepatocellular Carcinoma in KEYNOTE-240: A Randomized, Double-Blind, Phase III TrialRichard S Finn, Baek-Yeol Ryoo, Philippe Merle, et al.
Elife|March 23, 2021
Applications of genetic-epigenetic tissue mapping for plasma DNA in prenatal testing, transplantation and oncologyWanxia Gai, Ze Zhou, Sean Agbor-Enoh, et al.
HPB : the Official Journal of the International Hepato Pancreato Biliary Association|February 12, 2020
Prospective double-blinded randomized controlled trial of Microwave versus RadioFrequency Ablation for hepatocellular carcinoma (McRFA trial)Charing C N Chong, Kit F Lee, Sunny Y S Cheung, et al.
The Lancet. Oncology|July 7, 2022
Cabozantinib plus atezolizumab versus sorafenib for advanced hepatocellular carcinoma (COSMIC-312): a multicentre, open-label, randomised, phase 3 trialRobin Kate Kelley, Lorenza Rimassa, Ann-Lii Cheng, et al.
Annals of Internal Medicine|September 16, 2024
Viral Load-Based Prediction of Hepatocellular Carcinoma Risk in Noncirrhotic Patients With Chronic Hepatitis B : A Multinational Study for the Development and External Validation of a New Prognostic ModelGi-Ae Kim, Young-Suk Lim, Seungbong Han, et al.
Pageof 17